

Patricia J Eifel

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6802358/publications.pdf>

Version: 2024-02-01

54
papers

4,683
citations

279778
23
h-index

175241
52
g-index

55
all docs

55
docs citations

55
times ranked

3603
citing authors

#	ARTICLE	IF	CITATIONS
1	Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. <i>Cancer Immunology Research</i> , 2022, 10, 259-271.	3.4	10
2	Long-term survival following definitive radiation therapy for recurrence or oligometastases in gynecological malignancies: A landmark analysis. <i>Gynecologic Oncology</i> , 2022, 164, 550-557.	1.4	7
3	Use of Specific Duodenal Dose Constraints During Treatment Planning Reduces Toxicity After Definitive Paraaortic Radiation Therapy for Cervical Cancer. <i>Practical Radiation Oncology</i> , 2022, 12, e207-e215.	2.1	2
4	A phase III study of transdermal granisetron versus oral ondansetron for women with gynecologic cancers receiving pelvic chemoradiation. <i>Supportive Care in Cancer</i> , 2021, 29, 213-222.	2.2	2
5	A prospective study of the adaptive changes in the gut microbiome during standard-of-care chemoradiotherapy for gynecologic cancers. <i>PLoS ONE</i> , 2021, 16, e0247905.	2.5	20
6	Developing an intraoperative 3T MRI-guided brachytherapy program within a diagnostic imaging suite: Methods, process workflow, and value-based analysis. <i>Brachytherapy</i> , 2020, 19, 427-437.	0.5	12
7	Clinical utility and value contribution of an MRI-positive line marker for image-guided brachytherapy in gynecologic malignancies. <i>Brachytherapy</i> , 2020, 19, 305-315.	0.5	6
8	Pelvic fractures and changes in bone mineral density after radiotherapy for cervical, endometrial, and vaginal cancer: A prospective study of 239 women. <i>Cancer</i> , 2020, 126, 2607-2613.	4.1	20
9	Quantifying institutional resource utilization of adjuvant brachytherapy and intensity-modulated radiation therapy for endometrial cancer via time-driven activity-based costing. <i>Brachytherapy</i> , 2019, 18, 445-452.	0.5	16
10	IMRT all the way. <i>International Journal of Radiation Oncology Biology Physics</i> , 2019, 105, 692-693.	0.8	0
11	Adjuvant combined-modality therapy for stage IIIC endometrioid and non-endometrioid endometrial cancer. <i>Gynecologic Oncology</i> , 2019, 154, 22-28.	1.4	23
12	High intermediate risk endometrial cancer. What is it?. <i>International Journal of Gynecological Cancer</i> , 2019, 29, 1084-1085.	2.5	4
13	Effectiveness of definitive radiotherapy for squamous cell carcinoma of the vulva with gross inguinal lymphadenopathy. <i>Gynecologic Oncology</i> , 2018, 148, 474-479.	1.4	24
14	Outcomes and patterns of relapse after definitive radiation therapy for oligometastatic cervical cancer. <i>Gynecologic Oncology</i> , 2018, 148, 132-138.	1.4	53
15	Kinetics of Intratumoral Immune Cell Activation During Chemoradiation for Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, 593-600.	0.8	35
16	Challenges to delivery and effectiveness of adjuvant radiation therapy in elderly patients with node-positive vulvar cancer. <i>Gynecologic Oncology</i> , 2017, 146, 87-93.	1.4	15
17	In Reply to Mazon et al. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 97, 639.	0.8	0
18	Role of radiation therapy. <i>Best Practice and Research in Clinical Obstetrics and Gynaecology</i> , 2017, 41, 118-125.	2.8	7

#	ARTICLE	IF	CITATIONS
19	Impact of treatment year on survival and adverse effects in patients with cervical cancer and paraortic lymph node metastases treated with definitive extended-field radiation therapy. <i>Practical Radiation Oncology</i> , 2017, 7, e165-e173.	2.1	9
20	Patterns of recurrence and survival in neuroendocrine cervical cancer. <i>Gynecologic Oncology</i> , 2016, 143, 552-557.	1.4	35
21	Comparison of Computed Tomography and Magnetic Resonance Imaging-based Clinical Target Volume Contours at Brachytherapy for Cervical Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 96, 793-800.	0.8	18
22	Consensus Recommendations for Radiation Therapy Contouring and Treatment of Vulvar Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2016, 95, 1191-1200.	0.8	83
23	High-Grade Cervical Dysplasia following Radiation Therapy for Invasive Cervical Cancer: A Report of Four Cases. <i>Case Reports in Oncology</i> , 2015, 8, 217-221.	0.7	3
24	Radiotherapy for recurrent small cell carcinoma of the ovary: A case report and review of the literature. <i>Gynecologic Oncology Reports</i> , 2015, 11, 23-25.	0.6	18
25	Significance of lymph node ratio in defining risk category in node-positive early stage cervical cancer. <i>Gynecologic Oncology</i> , 2015, 136, 48-53.	1.4	79
26	Optimizing packing contrast for MRI-based intracavitary brachytherapy planning for cervical cancer. <i>Brachytherapy</i> , 2015, 14, 385-389.	0.5	3
27	Survival outcomes for patients with stage IVB vulvar cancer with grossly positive pelvic lymph nodes: Time to reconsider the FIGO staging system?. <i>Gynecologic Oncology</i> , 2015, 136, 269-273.	1.4	21
28	Trends in the Quality of Treatment for Patients With Intact Cervical Cancer in the United States, 1999 Through 2011. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 260-267.	0.8	41
29	Management of nodal recurrences of endometrial cancer with IMRT. <i>Gynecologic Oncology</i> , 2015, 139, 40-46.	1.4	28
30	Cancer of the vulva. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S76-83.	2.3	43
31	Cancer of the vagina. <i>International Journal of Gynecology and Obstetrics</i> , 2015, 131, S84-7.	2.3	42
32	Relationship Between Low Hemoglobin Levels and Outcomes After Treatment With Radiation or Chemoradiation in Patients With Cervical Cancer: Has the Impact of Anemia Been Overstated?. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 91, 196-205.	0.8	39
33	A review of safety, quality management, and practice guidelines for high-dose-rate brachytherapy: Executive summary. <i>Practical Radiation Oncology</i> , 2014, 4, 65-70.	2.1	47
34	Curative Radiation Therapy for Locally Advanced Cervical Cancer: Brachytherapy Is NOT Optional. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 537-539.	0.8	165
35	Variable impact of intracavitary brachytherapy fractionation schedule on biologically effective dose to organs at risk in patients with cervical cancer. <i>Brachytherapy</i> , 2014, 13, 240-249.	0.5	1
36	Dosimetric Predictors of Duodenal Toxicity After Intensity Modulated Radiation Therapy for Treatment of the Para-aortic Nodes in Gynecologic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2014, 88, 357-362.	0.8	62

#	ARTICLE	IF	CITATIONS
37	In Regard to Han et al. International Journal of Radiation Oncology Biology Physics, 2014, 88, 459-460.	0.8	29
38	Patterns of Radiation Therapy Practice for Patients Treated for Intact Cervical Cancer in 2005 to 2007: A Quality Research in Radiation Oncology Study. International Journal of Radiation Oncology Biology Physics, 2014, 89, 249-256.	0.8	77
39	Anatomic distribution of [18 F] fluorodeoxyglucose-avid lymph nodes in patients with cervical cancer. Practical Radiation Oncology, 2013, 3, 45-53.	2.1	21
40	Pilot study of a computed tomography-compatible shielded intracavitary brachytherapy applicator for treatment of cervical cancer. Practical Radiation Oncology, 2013, 3, 115-123.	2.1	4
41	Intensity modulated radiation therapy for definitive treatment of paraortic relapse in patients with endometrial cancer. Practical Radiation Oncology, 2013, 3, e21-e28.	2.1	23
42	The value of pelvic radiation therapy after hysterectomy for early endometrial cancer. Oncology, 2013, 27, 990-9.	0.5	3
43	Regional treatment of vulvar cancer; lessons from the past and lessons for the future. Practical Radiation Oncology, 2012, 2, 279-281.	2.1	1
44	Metastatic adenocarcinoma found in inguinal, pelvic and para-aortic lymph nodes 14 years following hysterectomy for adenocarcinoma in situ of the cervix. Gynecologic Oncology Case Reports, 2012, 2, 97-99.	0.9	2
45	Novel technique for simulation and external beam treatment planning for obese patients. Practical Radiation Oncology, 2011, 1, 152-155.	2.1	9
46	Node-positive adenocarcinoma of the endometrium: Outcome and patterns of recurrence with and without external beam irradiation. Gynecologic Oncology, 2009, 115, 6-11.	1.4	111
47	Predictive Value of a Proposed Subclassification of Stages I and II Cervical Cancer Based on Clinical Tumor Diameter. International Journal of Gynecological Cancer, 2009, 19, 2-7.	2.5	32
48	Chemoradiotherapy in the Treatment of Cervical Cancer. Seminars in Radiation Oncology, 2006, 16, 177-185.	2.2	75
49	Concurrent chemotherapy and radiation therapy as the standard of care for cervical cancer. Nature Clinical Practice Oncology, 2006, 3, 248-255.	4.3	64
50	Patterns of radiotherapy practice for patients with carcinoma of the uterine cervix: A patterns of care study. International Journal of Radiation Oncology Biology Physics, 2004, 60, 1144-1153.	0.8	118
51	Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical Cancer: An Update of Radiation Therapy Oncology Group Trial (RTOG) 90-01. Journal of Clinical Oncology, 2004, 22, 872-880.	1.6	903
52	Correlation of Smoking History and Other Patient Characteristics With Major Complications of Pelvic Radiation Therapy for Cervical Cancer. Journal of Clinical Oncology, 2002, 20, 3651-3657.	1.6	174
53	Pelvic Radiation with Concurrent Chemotherapy Compared with Pelvic and Para-Aortic Radiation for High-Risk Cervical Cancer. New England Journal of Medicine, 1999, 340, 1137-1143.	27.0	2,026
54	Intracavitary brachytherapy in the treatment of gynecologic neoplasms. , 1997, 66, 141-148.		15